Interface Biosciences is an AI-enabled metabolomics-based drug discovery engine. Inflammatory Disease is a huge unmet need. IBD, eczema, and rheumatoid arthritis all have millions of patients with billion dollar markets. Despite this, today's drugs are poor given the high magnitude and complexity of disease pathology. Current technology optimizes for a single parameter to a single target, making efficacy only as good as the effect on a single pathway. The microbiome, in contrast, has co-evolved with humans for millions of years, optimizing for multi-target immune modulating molecules. Interface Bio’s full-stack pipeline builds better biological data sets for modern machine learning and fully unlocks the potential of AI-driven biology for drug discovery. By systematically mining the microbial space, they discover tomorrow's blockbuster drugs for inflammatory disease.